Member Info for L2analyst

BRUSSELS, Feb 16 (Reuters) – The European Union is adding clauses to contracts with COVID-19 vaccine makers which would allow the bloc to gain access to possible upgraded shots that may offer better protection against variants of the virus, three EU sources said.

More contagious mutations are spreading fast in the EU and across the world, with the so-called British variant seen by experts as likely to become prevalent on the continent.

In new contracts with vaccine manufacturers, the EU is adding clauses that explicitly cover variants, three EU officials involved in talks with the companies told Reuters.

Vaccine makers are testing their shots against variants and are also working on tweaks that could make them more effective against virus mutations.

One official said the clauses would allow the EU not to buy vaccines that are not effective against widespread variants, and to order upgraded versions instead. However, the source said clauses were vague on the definition of variants and the actual legal power they would give the EU.

The three officials said that an anti-variant clause was included in a second contract finalised earlier in February with Pfizer and BioNTech for the supply of 300 million additional doses of their COVID-19 vaccine ....

Pfizer and the European Commission did not immediately respond to requests for comment.

Studies have shown the Pfizer vaccine can be effective against the British and the South African variants. The company is also working on a booster shot that would be tailored against variants.

The EU now wants to add these clauses in new supply deals and is considering whether to upgrade its existing contracts, the officials said.

The bloc is negotiating new supply agreements with Novavax , Valneva and Moderna to increase its vaccine reserve beyond the nearly 2.3 billion doses which it has already secured from six pharmaceutical firms ....

On Wednesday, the EU Commission will present a series of measures to boost the EU preparedness against variants, including new funds to help sequence the genome of the new coronavirus and spot variants ....

Most EU countries have so far done little or no sequencing at all ....

This share is prime for a takeover

Buys are overtaking the sells

I really like this share so its worth reading this again

Fifteen vaccine candidates containing different S and N components combined with a variety of targeting technologies were evaluated for the best T cell and antibody responses. SN14 reproducibly elicited high-titre anti-S virus neutralising antibodies (VNAbs) together with high avidity T cells against both the S and N proteins. SN14 also incorporates Scancell's AvidiMab™ technology to further enhance this immune response demonstrating the broad potential of this platform technology to generate improved vaccines for both infectious diseases and cancer.

 

SN14 is a second generation vaccine which offers several potential advantages over currently approved and late-stage COVID-19 vaccines:

· Not only does SN14 target the S protein to induce VNAbs that prevent the COVID-19 virus from entering cells but also induces strong T cell responses to both the S and N proteins to destroy virally-infected cells and prevent further viral replication.

· As the N protein is well-conserved between coronaviruses, the SN14 vaccine has the potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.

· Use of the AvidiMab™ technology increases the potency of the T cell response which, in turn, should lead to long-term protection and immunological memory.

· DNA vaccines are exceptionally stable, do not require ultra-low temperature storage and are manufactured using

Just got few shares, I cant see big pharmaceutical not taking interest in this

  Share PricesScancell Holdings Share PriceScancell Holdings Regulatory NewsCOVID-19 vaccine candidate selectedScancell Holdings Regulatory News (SCLP)SCLP Share
PriceSCLP Share
NewsSCLP Share
Chat90SCLP Share
Trades388SCLP
Live RNS

SCLP Information 

 Buy SCLP SharesAdd SCLP to WatchlistAdd SCLP to AlertAdd SCLP to myTerminal 

Share Price Information for Scancell Holdings (SCLP)

 Share Price is delayed by 15 minutes

Get Live Data

Share Price:23.40

Bid:23.30

Ask:23.50

Change:2.40 (11.43%) 

Spread: 0.200 (0.85%)

Open: 20.75

High: 23.50

Low: 22.50

Yest. Close: 21.00

Last checked at 10:32:17

COVID-19 vaccine candidate selected

Fri, 18th Dec 2020 07:00

RNS Number : 0847J

Scancell Holdings Plc

18 December 2020

 

18 December 2020

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell announces selection of COVID-19 vaccine candidate, SN14

 

SN14 offers several potential advantages over currently approved and late-stage COVID-19 vaccines

 

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies is pleased to announce that they have selected their COVID-19 vaccine candidate, SN14, for further development and clinical trials. SN14 targets both the SARS-CoV-2 nucleocapsid (N) protein and the key receptor-binding domain (RBD) of the spike (S) protein, and is based on a modification of Scancell's ImmunoBody® DNA vaccine technology.

 

Fifteen vaccine candidates containing different S and N components combined with a variety of targeting technologies were evaluated for the best T cell and antibody responses. SN14 reproducibly elicited high-titre anti-S virus neutralising antibodies (VNAbs) together with high avidity T cells against both the S and N proteins. SN14 also incorporates Scancell's AvidiMab™ technology to further enhance this immune response demonstrating the broad potential of this platform technology to generate improved vaccines for both infectious diseases and cancer.

 

SN14 is a second generation vaccine which offers several potential advantages over currently approved and late-stage COVID-19 vaccines:

· Not only does SN14 target the S protein to induce VNAbs that prevent the COVID-19 virus from entering cells but also induces strong T cell responses to both the S and N proteins to destroy virally-infected cells and prevent further viral replication.

· As the N protein is well-conserved between coronaviruses, the SN14 vaccine has the potential to be effective against any variant or new strain of coronavirus in addition to the current COVID-19 strain.

· Use of the AvidiMab™ technology increases the potency of the T cell response which, in turn, should lead to long-term protection and immunological memory.

· DNA vaccines are exceptionally stable, do not require ultra-low temperature storage and are manufactured using

This one and n4p has to be in the radar of major pharmaceutical companies

From 14p to 10p with high volume of trade , should bounce back up due to news in weeks time

10.35p to buy now

Added 25k shares only retrace well over done

Very nice rise here, kmk is worth alook

Theres something very different about this time placing, I really like the covid detection automated machine

Its ok thanks for reminding,, even a small amount of buy its 18.25p

Worth having a look at kmk also

Our system will be vital for NHS hospitals, its practical and viable

https://www.ft.com/content/07f76b06-73db-4647-97b6-ef0a9a58626d

I think some major contracts won by kmk hence quick placing, I have added cant afford to miss out

https://www.ft.com/content/07f76b06-73db-4647-97b6-ef0a9a58626d

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com

UK government to pump up to £43bn into Covid testing Contracts to include supply of millions of fast turnround tests seen as vital in fight against virus Point-of-care tests are being used in mass coronavirus testing trials in Liverpool © Christopher Furlong/Getty Share on Twitter (opens new window) Share on Facebook (opens new window) Share on LinkedIn (opens new window) Share on Whatsapp (opens new window) Save Anna Gross in London and Andy Bounds in Huddersfield NOVEMBER 10 2020 111 The UK government is preparing to make nearly £43bn available to companies that can help deliver on its mass Covid-19 testing vision, which aims to roll out rapid turnround tests across the country. Private and public sector organisations are being invited to apply for three tenders for the supply of new testing technologies as part of prime minister Boris Johnson’s so-called “Project Moonshot” testing programme. It is anticipated that hundreds of companies will apply to supply products and services to the government as part of the open procurement process.

Wonder if they are sending signal to apple

"Three-year exclusive brand ambassador contract with NFL star Richard Sherman, Super Bowl Champion. Richard Sherman was previously a brand ambassador for Beats headphones, which was acquired by Apple.

Very nice article

Crucially, Nuvec can be formulated with plasmid DNA, dried and stored at room temperature or in the fridge at 4 °C for at least 14 days (with further work under way to test longer time periods), then reconstituted without any degradation of DNA — all while maintaining good transfection.

This is important because a stable, easy to store and use vaccine is a major challenge for developers.

https://www.barchart.com/stocks/quotes/N4P.LN/overview